Physician profile
Michael Radonich
NPI 1053404681
$1,427.05
in general payments reported to CMS, 2019-2025
13 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $108 · 2021: $239 · 2022: $141 · 2023: $216 · 2024: $150 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $757.53 | 2019-2022 | |
| Amgen INC. | $246.79 | 2023-2025 | Otezla |
| Leo Pharma INC. | $101.59 | 2025 | Anzupgo, Adbry |
| Mayne Pharma Commercial LLC | $69.34 | 2019 | |
| Janssen Biotech, INC. | $56.82 | 2023-2024 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.70 | 2021-2023 | Targretin, Siliq |
| Organon LLC | $31.38 | 2025 | Vtama |
| Kci USA, INC. | $31.21 | 2023 | Prevena |
| Smith+Nephew, INC. | $22.50 | 2023 | Renasys Go V2 Home |
| Almirall LLC | $19.95 | 2025 | Klisyri |
| Prugen, INC. Pharmaceuticals | $19.06 | 2019 | |
| Galderma Laboratories, L.P. | $16.34 | 2025 | Aklief |
| Journey Medical Corporation | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Radonich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.